Cryo-Cell International, Inc. (CCEL) Cash Flow Statement
Where CCEL’s cash came from and went, FY2025
November 30, 2025 · U.S. dollars- Cash from operations
- $5.5M −8.9% vs FY2024
- Capital expenditures
- $230,475 0.7% of revenue
- Free cash flow
- $5.2M 16.6% margin
- Returned to shareholders
- $3.4M 65% of free cash flow
- Change in cash
- −$241,929 cash at year-end $319,031
Drawn to scale: where the cash came from and how it was used. Hover for values.
CCEL operating cash flow, capex and free cash flow
CCEL cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $5.0MFY2016 | $5.5MFY2025 | +1.0%/yr | |
| Capital expenditures | $342,982FY2016 | $230,475FY2025 | −4.3%/yr | |
| Free cash flow | $4.6MFY2016 | $5.2MFY2025 | +1.4%/yr | |
| Free cash flow margin | 20.1%FY2016 | 16.6%FY2025 | −3.5 pts | |
| Operating cash flow / net income | 2.47FY2017 | 14.95FY2024 | +12.48 | |
| Stock-based compensation | $1.8MFY2016 | $417,101FY2025 | −14.8%/yr | |
| Dividends paid | $0FY2016 | $3.2MFY2025 | — | |
| Share buybacks (net) | $10.8MFY2016 | $169,502FY2025 | −37.0%/yr | |
| Capex / revenue | 1.5%FY2016 | 0.7%FY2025 | −0.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CCEL cash flow by activity
CCEL net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CCEL cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$2.4M | $402,095 | −$9.5M | $2.8M | $2.1M | $3.6M | $2.3M | −$854,824 | $2.3M | −$1.3M |
| Depreciation & amortization | $1.4M | $1.0M | $1.7M | $1.8M | $1.3M | $635,975 | $401,311 | $317,326 | $229,995 | $286,650 |
| Stock-based compensation | $417,101 | $781,128 | $816,639 | $461,345 | $301,616 | $622,120 | $397,770 | $478,378 | $971,730 | $1.8M |
| Change in working capital | $2.8M | $3.7M | $6.0M | $4.3M | $4.9M | $3.8M | $2.3M | $2.4M | $2.8M | $1.5M |
| Other non-cash items | $3.3M | $107,724 | $9.9M | −$719,853 | −$642,123 | −$171,851 | $952,326 | $3.0M | −$572,360 | $2.7M |
| Cash from operating activities | $5.5M | $6.0M | $8.9M | $8.6M | $7.9M | $8.5M | $6.3M | $5.3M | $5.7M | $5.0M |
| Investing activities | ||||||||||
| Capital expenditures | −$230,475 | −$3.6M | −$7.6M | −$17.2M | −$7.0M | −$449,962 | −$662,295 | −$646,163 | −$98,333 | −$342,982 |
| Investments (net) | −$859,857 | −$4.9M | −$8.1M | −$15.3M | −$7.0M | $457,447 | −$28,364 | −$136,248 | $191,358 | −$369,728 |
| Acquisitions & other investing | $115,000 | $3.6M | $7.6M | $17.2M | $7.0M | $350,000 | $0 | −$10.5M | $0 | $342,982 |
| Cash from investing activities | −$975,332 | −$4.9M | −$8.1M | −$15.3M | −$7.0M | $357,485 | −$690,659 | −$11.3M | $93,025 | −$369,728 |
| Financing activities | ||||||||||
| Dividends paid | −$3.2M | −$2.0M | $0 | −$7.7M | $0 | — | — | $0 | $0 | $0 |
| Share repurchases & issuance (net) | −$169,502 | −$1.4M | −$799,036 | −$1.8M | −$249,377 | $41,000 | −$992,244 | $170,925 | −$446,621 | −$10.8M |
| Net borrowing (repayment) | −$1.4M | $2.2M | −$1.2M | $9.3M | −$4.1M | −$3.1M | −$4.1M | $5.5M | −$2.6M | $9.3M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $23,101 | $304,402 | −$67,500 | $354,773 | $1.3M | −$1.9M | −$39,300 | $0 | $64,696 | −$3.7M |
| Cash from financing activities | −$4.7M | −$979,118 | −$2.1M | $147,862 | −$3.1M | −$5.0M | −$5.1M | $5.7M | −$3.0M | −$5.3M |
| Summary | ||||||||||
| Net change in cash | −$241,929 | $154,893 | −$1.3M | −$6.6M | −$2.1M | $3.8M | $501,004 | −$239,121 | $2.8M | −$652,281 |
| Cash at end of period | $319,031 | $560,960 | $406,067 | $1.7M | $8.3M | $10.4M | $6.5M | $6.0M | $6.3M | $3.5M |
| Free cash flow | $5.2M | $2.4M | $1.3M | −$8.6M | $974,923 | $8.0M | $5.7M | $4.7M | $5.6M | $4.6M |
| Free cash flow margin | 16.6% | 7.5% | 4.1% | −28.3% | 3.4% | 25.7% | 17.8% | 16.0% | 22.1% | 20.1% |
| Capex / revenue | 0.7% | 11.3% | 24.4% | 56.6% | 24.1% | 1.4% | 2.1% | 2.2% | 0.4% | 1.5% |
| Operating cash flow / net income | — | 14.95 | — | 3.09 | 3.80 | 2.34 | 2.76 | — | 2.47 | — |
| Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $1.3M | $554,586 | $47,108 | −$3.8M | $749,408 | $355,785 | $282,855 | −$1.9M | $1.1M | $655,790 | $556,241 | −$11.2M |
| Depreciation & amortization | $333,439 | $343,529 | $341,999 | $330,233 | $353,630 | $344,259 | $339,996 | $339,448 | $332,472 | $188,495 | $161,182 | $409,910 |
| Stock-based compensation | $92,514 | $64,904 | $158,549 | $42,903 | $36,780 | $40,026 | $297,392 | $149,693 | $145,941 | $178,139 | $307,355 | $174,949 |
| Change in working capital | −$879,471 | $629,019 | −$354,764 | $2.9M | $783,576 | −$560,657 | −$274,034 | $3.5M | $1.1M | $576,094 | −$1.4M | $4.5M |
| Other non-cash items | $324,797 | $253,873 | $458,935 | $1.8M | $613,322 | $527,601 | $307,854 | $23,379 | −$155,043 | $174,963 | $64,425 | $9.4M |
| Cash from operating activities | $1.1M | $1.8M | $651,827 | $1.3M | $2.5M | $707,014 | $954,063 | $2.2M | $2.4M | $1.8M | −$356,865 | $3.3M |
| Investing activities | ||||||||||||
| Capital expenditures | −$101,879 | −$32,701 | −$67,065 | −$67,226 | −$38,788 | −$62,408 | −$62,053 | −$141,681 | −$319,039 | −$2.7M | −$457,722 | −$1.7M |
| Investments (net) | — | $67,740 | $86,169 | −$222,423 | — | −$1.5M | −$287,484 | −$1.1M | −$665,603 | −$2.8M | −$341,049 | −$2.0M |
| Acquisitions & other investing | −$78,872 | $0 | $0 | $0 | $1.1M | $62,408 | $62,053 | $141,681 | $319,039 | $2.7M | $457,722 | $1.7M |
| Cash from investing activities | −$180,751 | $35,039 | $19,104 | −$289,649 | $1.1M | −$1.5M | −$287,484 | −$1.1M | −$665,603 | −$2.8M | −$341,049 | −$2.0M |
| Financing activities | ||||||||||||
| Dividends paid | — | $0 | $0 | $0 | — | −$1.2M | −$2.0M | — | — | $0 | $0 | — |
| Share repurchases & issuance (net) | — | — | — | $0 | −$80,883 | −$88,619 | $0 | $0 | −$16,400 | −$1.2M | −$170,376 | $799,036 |
| Net borrowing (repayment) | — | −$1.6M | −$740,290 | −$937,340 | — | $2.0M | $1.0M | $1.3M | −$2.0M | $2.2M | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$42,657 | $23,250 | $0 | $0 | −$3.4M | $0 | $0 | −$1.9M | $1,002 | $228,000 | $709,335 | −$2.3M |
| Cash from financing activities | −$42,657 | −$1.6M | −$740,290 | −$937,340 | −$3.5M | $710,155 | −$1.0M | −$677,821 | −$2.0M | $1.2M | $538,959 | −$1.5M |
| Summary | ||||||||||||
| Net change in cash | $918,361 | $257,630 | −$69,359 | $53,824 | $127,716 | −$85,631 | −$337,838 | $363,523 | −$271,758 | $222,083 | −$158,955 | −$177,929 |
| Cash at end of period | $1.4M | $507,302 | $249,672 | $319,031 | $265,207 | $137,491 | $223,122 | $560,960 | $197,437 | $469,195 | $247,112 | $406,067 |
| Free cash flow | $1.0M | $1.8M | $584,762 | $1.2M | $2.5M | $644,606 | $892,010 | $2.0M | $2.1M | −$911,785 | −$814,587 | $1.6M |
| Free cash flow margin | 13.3% | 23.3% | 7.6% | 15.5% | 31.9% | 8.1% | 11.2% | 25.1% | 26.3% | −11.3% | −10.4% | 20.7% |
| Capex / revenue | 1.3% | 0.4% | 0.9% | 0.9% | 0.5% | 0.8% | 0.8% | 1.8% | 4.0% | 33.4% | 5.8% | 21.8% |
| Operating cash flow / net income | 0.90 | 3.33 | 13.84 | — | 3.38 | 1.99 | 3.37 | — | 2.32 | 2.70 | −0.64 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CCEL cash generation
In fiscal 2025 (ended November 30, 2025), Cryo-Cell International generated $5.5 million of cash from operations (down 8.9%) and spent $0.2 million on capital expenditures, leaving free cash flow of $5.2 million, 16.6% of revenue. It returned $3.4 million to shareholders through dividends ($3.2 million) and net share buybacks ($0.2 million). Cash and equivalents fell by $0.2 million over the year.
Related: CCEL income statement, CCEL balance sheet, CCEL dividend history. See the CCEL stock overview for the latest quote and news.
CCEL cash flow FAQ
What is Cryo-Cell International's free cash flow?
Cryo-Cell International's free cash flow was $5.2 million in fiscal 2025: $5.5 million of operating cash flow minus $0.2 million of capital expenditures It was $2.4 million a year earlier..
How much cash does Cryo-Cell International generate from operations?
Cryo-Cell International generated $5.5 million of cash from operating activities in fiscal 2025.
How much does Cryo-Cell International spend on capital expenditures?
Cryo-Cell International spent $0.2 million on capital expenditures in fiscal 2025, 0.7% of revenue, compared with $3.6 million the year before.
How much stock does Cryo-Cell International buy back?
Cryo-Cell International spent $0.2 million on net share repurchases in fiscal 2025.
How much does Cryo-Cell International pay in dividends?
Cryo-Cell International paid $3.2 million in dividends in fiscal 2025, 61.6% of free cash flow.